CAJ | 학술논문

目的观察阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者4年的疗效和安全性.方法 95例HBeAg阳性慢性乙型肝炎初治患者,口服阿德福韦酯10 mg,每日1次,观察治疗前后血清ALT和HBV DNA水平及治疗1、2、3、4年ALT复常率、HBV DNA阴转率、HBeAg消失率、HBeAg血清学转换率、病毒学反弹率及药物不良事件.结果 95例患者治疗4年时,ALT复常率、HBV DNA阴转率、HBeAg消失率、HBeAg血清学转换率及病毒学反弹率分别为89.5％、63.2％、47.4％、41.1％及8.0％.治疗过程中均未发现药物相关的肾脏毒性,共有8例患者出现轻度药物不良事件,但均能耐受和缓解.结论阿德福韦酯初始治疗HBeAg阳性慢性乙型肝炎患者,能有效抑制HBV DNA复制,促进ALT复常,促使HBeAg/HBeAb血清学转换.延长疗程,可增加HBV DNA阴转、HBeAg消失和血清学转换,具有良好的耐受性和安全性.
목적 관찰아덕복위지치료HBeAg양성만성을형간염환자4년적료효화안전성.방법 95례HBeAg양성만성을형간염초치환자,구복아덕복위지10 mg,매일1차,관찰치료전후혈청ALT화HBV DNA수평급치료1、2、3、4년ALT복상솔、HBV DNA음전솔、HBeAg소실솔、HBeAg혈청학전환솔、병독학반탄솔급약물불량사건.결과 95례환자치료4년시,ALT복상솔、HBV DNA음전솔、HBeAg소실솔、HBeAg혈청학전환솔급병독학반탄솔분별위89.5％、63.2％、47.4％、41.1％급8.0％.치료과정중균미발현약물상관적신장독성,공유8례환자출현경도약물불량사건,단균능내수화완해.결론 아덕복위지초시치료HBeAg양성만성을형간염환자,능유효억제HBV DNA복제,촉진ALT복상,촉사HBeAg/HBeAb혈청학전환.연장료정,가증가HBV DNA음전、HBeAg소실화혈청학전환,구유량호적내수성화안전성.
Objective To observe the efficacy and safety on the efficacy of HBeAg-positive chronic Hepatitis B patients treated with adefovir dipivoxil for 4 years.Methods Ninety-five patients with HBeAg-positive chronic hepatitis B were treated with adefovir dipivoxil 10 mg per day orally.The patients were observed before and after treatment for their serum levels of ALT and HBV DNA,the new increasing rates of serum ALT normalization,HBV DNA clearances,HBeAg loss,HBeAg seroconversion and adverse drug events.Results At 4 years on study,the rates of ALT normalization,HBV DNA clearances,HBeAg loss,HBeAg seroconversion and HBV DNA rebound were 89.5％,63.2％,47.4％,41.1％ and 8.0％,respectively.No drug related to renal function impairment was found during the treatment,eight patients had adverse drug events but all were mild.Conclusion Adefovir dipivoxil could effectively inhibit HBV replication,normalize ALT and enhance transformation from HBeAg to HBeAb for cases with naive and treated-first patients.The efficacy were increased with prolongation of the treatment period.It is safe and has a good tolerance.